Eleclazine

DB12394InvestigationalSmall molecule

Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic Heart Disease, Ventricular Arrhythmia, and Long QT Syndrome Type 3, among others.

Mechanism: Pharmacologically active on Sodium channel protein type 5 subunit alpha
Curator reviewed
Formula / weight: C₂₁H₁₆F₃N₃O₃ · 415.372 g/mol (avg)
Code names: GS-6615

Resolves to

Compound

UNIIPUY08529FKCAS1443211-72-0ChEMBLCHEMBL3707392PubChem71183216

Structure

InChIKeyYNUAEEJQYHYLMS-UHFFFAOYSA-NSMILESFC(F)(F)OC1=CC=C(C=C1)C1=CC=C2OCCN(CC3=NC=CC=N3)C(=O)C2=C1

Targets

Q14524SCN5A

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Eleclazine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account